Penil erektil fonksiyon her hekim tarafından sorgulanmalı mıdır?

Toplumsal ve sosyokültürel farklılıklar hastaların cinsel fonksiyonlar ile ilgili sorunlarını dile getirmesini güçleştir- mektedir. Gerek utanmaları gerekse erektil disfonksiyonu yaşlanmanın doğal bir sonucu olarak kabul etmeleri nede- niyle hastalar mevcut şikayetlerini kolayca ifade edemezler. Ayrıca erektil disfonksiyonun yaygın olduğunu ve teda- visinin büyük oranda mümkün olduğunu bilmezler. Tüm bu sebeplerle hastalar cinsel işlevler ile ilgili sorunlarının hekimler tarafından fark edilmesini ve sorgulanmasını beklerler. Hekimler de sorun odaklı çalışma tarzlarından dola- yı cinsel işlevler ile ilgili sorunları çoğunlukla sorgulamamaktadırlar. Bunun yanında bazı hekimler erektil disfonk- siyonun yüksek morbidite ve mortaliteye sahip diğer hastalıklara göre daha az önemli olduğunu düşünürler. Oysaki erektil disfonksiyon diyabet, koroner arter hastalığı, depresyon gibi diğer ciddi hastalıkların bir komponenti ve hatta ilk bulgusu olabilir. Ayrıca erektil disfonksiyon her yaşta görülebilen bir sorundur. Yapılan çalışmalarda 40 yaş üstü erkeklerde yaklaşık %52-69, 40 yaş altı erkeklerde yaklaşık %25-30 düzeylerinde saptanmıştır. Her yaşta görülebil- mesi, ciddi komorbiditeye sahip hastalıklar ile yakın ilişkisi, her iki cinsiyeti etkilemesi, kolay tanı konulabilir ve te- davisinin büyük oranda mümkün olması nedeni ile erektil disfonksiyon başta aile hekimleri olmak üzere tüm hekim- ler tarafından sorgulanması gereken önemli bir sağlık sorunudur.

Should penile erectile function be questioned by each physician?

Social and socio-cultural differences make it difficult to articulate issues related to sexual functions of patients. Due to both shame and acceptance of the situation as a natural consequence of aging, erectile dysfunction patients do not express their complaints easily. In addition, the patients do not know that erectile dysfunction is a common problem and it is possible to treat it to a large extent. For all these reasons, the patients expect their problems related to sexu- al functioning to be noticed and questioned by doctors. Doctors also tend not to question the problems with sexual functioning because of their problem-oriented working style. Besides, some doctors think that erectile dysfunction is less important than the other diseases having high morbidity and mortality. However, erectile dysfunction may be the first sign or even a component of the other serious diseases such as diabetes, coronary artery disease and depres- sion. In addition, erectile dysfunction is a problem that can be seen at any age. Studies demonstrated that 52-69% of men over 40 and 25-30% of men under 40 years of age have erectile dysfunction. Erectile dysfunction is a major he- alth problem and should be questioned by all physicians including family physicians because it is an easy-to be diag- nosed disease and treatable to a large extent, can be seen at any age, has a close relationship with the other diseases having serious comorbidity and affects both sexes.

PDF

___

1. Ende JE, Rockwell S, Glasgow M. The sexual history in general medicine practice. Arch Intern Med 1984;144:558-561.
2. Rutchik SD, Baudiere M, Wade M, Sullivan G, Rayford W, Go- odman J. Practice patterns in the diagnosis and treatment of erec- tile dysfunction among family practice physicians. Urology. 2001;57:146–150.
3. Nicolosi A, Laumann EO, Glasser DB, Moreira ED Jr, Paik A, Gingell C; Global Study of Sexual Attitudes and Behaviors Inves- tigators' Group. Sexual behavior and sexual dysfunctions after age 40: the global study of sexual attitudes and behaviors. Urology. 2004 Nov;64(5):991-7.
4. Atan A, Tekdoğan U, Akbulut Z, Gungor S, Yılmaz A, Aksut H. Üroloji uzmanı olmayan doktorlar, erkek hastada ereksiyon sorgu- laması yapıyor mu? Türk Üroloji Dergisi 2005;31: 212-216.
5. Platano GMA, Margraf JP, Alder JP, Bitzer JMD. Frequency and focus of sexual history taking in male patients: A pilot study con- ducted among Swiss general practitioners and urologists. J Sex Med 2008;5:47–59.
6. Ansong KS. Lewis C, Jenkins P. Help-seeking decisions among men with impotence. Urology 1998;52:834–837.
7. Kubin M, Wagner G, Fugl-Meyer AR. Epidemiology of erectile dysfunction. Int J Impot Res. 2003 Feb;15(1):63-71.
8. McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res. 2000 Oct;12:6-11.
9. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKin- lay JB. Impotence and its medical and psychosocial correla- tes: results of the Massachusetts Male Aging Study. J Urol. 1994 Jan;151(1):54-61.
10. Ponholzer A, Temml C, Mock K, Marszalek M, Obermayr R, Ma- dersbacher S. Prevalence and risk factors for erectile dysfuncti- on in 2869 men using a validated questionnaire. Eur Urol. 2005 Jan;47(1):80-6. 11.
11- Cheng JY, Ng EM, Ko JS, Chen RY. Physical activity and erec- tile dysfunction: meta-analysis of population-based studies. Int J Impot Res. 2007 May-Jun;19(3):245-52.
12. Bai Q, Xu QQ, Jiang H, Zhang WL, Wang XH, Zhu JC. Prevalen- ce and risk factors of erectile dysfunction in three cities of China: a community based study. Asian J Androl 2004;6:343–8.
13. Burger B, Weidner W, Altwein JE. Prostate and sexuality: an over- view. Eur Urol 1999;34:177-184.
14. Bretschneider JG, McCoy NL. Sexual interest and behavior in he- althy 80- to 102-year-olds. Arch Sex Behav. 1988 Apr;17(2):109-29.
15. Perelman M, Shabsigh R, Seftel A, Althof S, Lockhart D. Attitu- des of men with erectile dysfunction: a cross-national survey. J Sex Med. 2005 May;2(3):397-406.
16. Akkus E, Kadioglu A, Esen A, Doran S, Ergen A, Anafarta K, Hattat H; Turkish Erectile Dysfunction Prevalence Study Gro- up. Prevalence and correlates of erectile dysfunction in Turkey: a population-based study. Eur Urol. 2002 Mar;41(3):298-304.
17. Balcı M, Aslan Y, Aydın AO, Kayalı M, Tuncel A,Atan A. Türk er- keklerinde cinsel fonksiyon bozukluğu taraması: anket çalışması. Ortadoğu Tıp Dergisi 2012;4(3):108-113.
18. Miner M. Health care cost implications of sildenafil citrate. J Sex Med. 2004 Sep;1(2):141-9.
19. Swindle RW, Cameron AE, Lockhart DC, Rosen RC. The psycho- logical and interpersonal relationship scales: assessing psycholo- gical and relationship outcomes associated with erectile dysfuncti- on and its treatment. Arch Sex Behav. 2004 Feb;33(1):19-30. 106 ORTADOĞU TIP DERGİSİ 5 (2): 103-106 2013
20. MacDonagh R, Ewings P, Porter T. The effect of erectile dysfunc- tion on quality of life: psychometric testing of a new quality of life measure for patients with erectile dysfunction. J Urol. 2002 Jan;167(1):212-7.
21. Shamloul R, Ghanem H. Erectile dysfunction. - Lancet. 2013 Jan 12;381(9861):153-65.
22. Montorsi P, Ravagnani PM, Galli S, Rotatori F, Veglia F, Brigan- ti A, Salonia A, Dehò F, Rigatti P, Montorsi F, Fiorentini C. As- sociation between erectile dysfunction and coronary artery di- sease. Role of coronary clinical presentation and extent of coro- nary vessels involvement: the COBRA trial. Eur Heart J. 2006 Nov;27(22):2632-9.
23. Pritzker M. The penile stress test: a window to the hearts of man? Circulation 1999;100 (suppl 1):1–711.
24. 24-Montorsi P, Ravagnani PM, Galli S, Salonia A, Briganti A, Werba JP, Montorsi F. Association between erectile dysfunction and coronary artery disease: Matching the right target with the right test in the right patient. Eur Urol. 2006 Oct;50(4):721-31.
25. Sadovsky R. Erectile dysfunction is a signal of risk for significant medical comorbidities: A primary care view Current Sexual Health Reports 2004 1(4):129-136.
26. Curkendall SM, Jones JK, Pezzulo JC. Relationship of medical de- tection of erectile dysfunction to detection of related diseases after the introduction of sildenafil citrate. Eur. Urol. 2000;37 (Suppl 2):81
27. Billups K, Friedrich S. Assessment of fasting lipid panels and Doppler ultrasound testing in men presenting with erectile dysfunction and no other medical problems. J UroI 2000; 163 (4) Suppl:147.
28. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998:338;1397-404.
29. Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulb- rich E, et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erec- tile dysfunction: the first at-home clinical trial. Int J Impot Res 2001:13;192-9. 30.
30- Martin-Morales A, Meijide F, García N, Artes M, Muñoz A.Efficacy of vardenafil and influence on self-esteem and self- confidence in patients with severe erectile dysfunction. J Sex Med 2007:4;440-7. 31.
31- Park HJ, Park JK, Park K, Min K, Park NC. Efficacy of ude- nafil for the treatment of erectile dysfunction up to 12 hours after dosing: a randomized placebo-controlled trial. - J Sex Med. 2010 Jun;7(6):2209-16.